C4 Therapeutics, Inc. (NASDAQ: CCCC) had its price target raised by analysts at Wells Fargo & Company from $7.00 to $8.00. They now have an "equal weight" rating on the stock.
LowReport
C4 Therapeutics, Inc. (NASDAQ: CCCC) had its price target raised by analysts at Wells Fargo & Company from $7.00 to $8.00. They now have an "equal weight" rating on the stock.
C4 Therapeutics, Inc. (NASDAQ: CCCC) had its price target raised by analysts at Stifel Nicolaus from $13.00 to $14.00. They now have a "buy" rating on the stock.
LowReport
C4 Therapeutics, Inc. (NASDAQ: CCCC) had its price target raised by analysts at Stifel Nicolaus from $13.00 to $14.00. They now have a "buy" rating on the stock.
C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024 [Yahoo! Fina
LowReport
C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024 [Yahoo! Fina
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
"Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ blog email newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our blog below: